Several genes have been identified as epigenetic targets of RNF2; for example, cyclin-dependent kinase inhibitors 1A and 2A (CDKN1A and CDKN2A) were shown to be RNF2 targets in hepatic stem/progenitor cells [27], and thioredoxin interacting protein was reported to be an RNF2 target in prostate cancer [28]. Here, CDKN1A is linked to prostate cancer.